Open Access

Association of IL-10, IL-4, and IL-28B gene polymorphisms with spontaneous clearance of hepatitis C virus in a population from Rio de Janeiro

  • Juliene Antonio Ramos1, 2,
  • Rosane Silva1, 6,
  • Luísa Hoffmann1,
  • Ana Lucia Araújo Ramos3, 4,
  • Pedro Hernan Cabello5,
  • Turán Péter Ürményi1,
  • Cristiane Alves Villella-Nogueira3, 4,
  • Lia Lewis-Ximenez5 and
  • Edson Rondinelli1, 4, 6Email author
BMC Research Notes20125:508

DOI: 10.1186/1756-0500-5-508

Received: 12 March 2012

Accepted: 12 September 2012

Published: 17 September 2012



Cytokines play an important role in the regulation of the immune response. In hepatitis C virus (HCV) infection, cytokine levels may influence the outcome of acute HCV infection. Polymorphisms in cytokine genes have been associated to different expression levels in response to infection. This study was carried out to investigate the association of several cytokine gene polymorphisms with disease outcome in HCV-infected patients.


Patients with chronic or spontaneously resolved HCV infection were included in a cross-sectional study. A comparative analysis was performed between the groups regarding frequency distribution of the following cytokines’ gene polymorphisms: IL-10 (−1082 A/G; -819 T/C; -592 A/C), IL-4 (+33C/T), IFN-γ (+874 T/A), TNF-α (−238 G/A and −308 G/A) and IL-28B (rs12979860 C/T and rs8099917 T/G). Results: Eighteen patients with spontaneous viral clearance and 161 with chronic HCV infection were included. In the comparative analysis, the GG genotype of the IL-10 polymorphism -1082A/G was more frequent in patients with spontaneous viral clearance when compared to patients with chronic HCV (41.2% vs 6.2%; p = 0.001). This association was also found for the CC genotype of the IL-4 polymorphism +33C/T (72.2% vs 36.7%; p = 0.017) and the CC and TT genotypes of the IL-28B polymorphisms rs 12979860 and rs 8099917 (88.9% vs 30.3%; p < 0.001 and 88.9% vs 49.6%; p = 0.002). The IL10 (A-1082 G) and IL-28B (Crs12979860T) gene polymorphisms showed odds ratios of 12.848 and 11.077, respectively, and thus may have a greater influence on HCV spontaneous viral clearance. The IFN-γ (+874 T/A), TNF-α (−238 G/A and −308 G/A) polymorphisms did not show significant association with spontaneous viral clearance or chronicity.


The G allele for IL-10 (−1082 A/G), the C allele for IL-4 (+3 C/T) and the C and T alleles for IL-28B (rs12979860 and rs8099917, respectively) are associated with spontaneous viral clearance in hepatitis C infection.


Acute hepatitis C Chronic hepatitis C HCV Spontaneous viral clearance Cytokines Gene polymorphism



Hepatitis C virus (HCV) infection is one of the leading causes of liver disease with approximately 180 million people chronically infected worldwide[1]. Most HCV-infected patients (70-80%) develop chronic hepatitis, which in some cases progress to liver cirrhosis (15-20%) and hepatocellular carcinoma (1-5%). Patients with spontaneous viral clearance are difficult to identify since this outcome occurs mainly in the acute phase of HCV infection, which is rarely recognized due to the lack of symptoms and signs of liver disease.

Factors related to development of persistent infection, which occurs in the great majority of cases, or to spontaneous viral clearance, are not well defined. The individual susceptibility and the outcome of HCV infection have been associated to polymorphisms of cytokines genes[25], and pathogenesis is related to the genotype of the virus as well as the immune response of the host[6, 7].

The impact of the cytokine gene polymorphisms in the pathogenesis of HCV infection has also been investigated[814]. Recently, a number of studies have reported that polymorphisms near the gene for IL-28B are strongly correlated with treatment response in patients with chronic hepatitis C and also with spontaneous viral clearance[15, 16]. The aim of this study was to investigate whether SNPs in genes involved in humoral and cellular immune responses as well as in genes associated with activation of the antiviral state influence the outcome of the disease towards spontaneous viral clearance or chronicity. The gene polymorphisms selected were chosen according to their described role in immune and inflammatory responses: TH1 response, IFN-γ (+874) and TNF-α (−308 and −238); TH2 response, IL-4 (+33) and IL-10 (−1082; -819 and −592); activation of the antiviral state, IL-28B rs 12979860 and rs 8099917.

Patient characteristics

Baseline demographic of 18 patients with acute hepatitis C that progressed to spontaneous viral clearance, and 161 with chronic hepatitis C, are summarized in Table 1. Patients from both groups did not differ significantly in age (p = 0.108), gender (p = 0.145) or HCV genotype (p = 0.149). The sample size of acute hepatitis C patients is small due to the fact that patients in this phase frequently go undetected, and thus are difficult to identify. However, the statistical analysis that we performed on the data takes into account the low number of patients obtained.
Table 1

Demographic and virological features of patients with HCV infection


Acute hepatitis C with viral clearance N = 18 (%)

Chronic hepatitis C N = 161 (%)


Sex (number)




77 (55.4%)




84 (44.6%)


Age (years)

44.4 (21–73)



Viral genotype



16 (88.9%)

125 (77.6%)



02 (11.1%)

36 (22.4%)


Association of cytokine genotype and allele frequencies with the disease outcome

Patients were genotyped for IL-10 (−592C/A, -819C/T and -1082A/G) IL-4 (+33C/T), IFN-γ (+874 T/A), TNF-α (−238 G/A, -308 G/A) and IL-28B (rs12979860C/T and rs8099917T/G) gene polymorphisms. Table 2 shows the distribution of allele and genotype frequencies for the two groups. There were significant differences in the genotype distribution of IL-10 (−1082A/G) (OR 3.931, CI 1.938-7.973, p = 0.001), IL-4 (+33C/T) (OR 3.879, CI 1.655-9.089, p = 0.004), and IL-28B (rs8099917T/G and rs12979860C/T) (OR 5.021, CI 1.9-13.267 p = 0.002 and OR 5.707, CI 2.154-15.124, p < 0.001, respectively) polymorphisms. A higher frequency of GG genotype of the −1082 polymorphism of the IL-10 (41.2%) and a higher frequency of CC for +33 IL-4 polymorphism (72.2%) were observed in patients with acute hepatitis with spontaneous viral clearance than in patients with chronic hepatitis C (6.2% and 36.7% respectively; p < 0.05) It is worth mentioning that all patients with spontaneous viral clearance showed GG genotype of the −1082 polymorphism of the IL-10 together with CC genotype of the polymorphism of IL-4 +33, forming a diplotype GGCC. For the polymorphisms in the gene IL-28 gene, patients with acute hepatitis with spontaneous viral clearance had a higher frequency of TT genotype (88.9%) of the polymorphism rs8099917 and CC genotype (88.9%) of the polymorphism rs12979860. In assessing the diplotype for these two polymorphisms we found that all patients with the TT genotype of rs8099917 polymorphism also had the CC genotype polymorphism for rs12979860. Thus, the diplotype TTCC was present in 88.9% of patients who spontaneously cleared the virus.
Table 2

Genotype and allele frequencies of cytokine genotypes in patients with acute hepatitis C with viral clearance and patients with chronic hepatitis C

Gene polymorphism

Genotype and allele

Acute hepatitis C with viral clearance

Chronic hepatitis C




n = 17

n = 161




07 (41.2%)

106 (65.8%)



03 (17.6%)

45 (28%)



07 (41.2%)

10 (6.2%)




17 (50%)

257 (79.8%)



17 (50%)

65 (20.2%)




08 (47.1%)

58 (36%)



05 (29.4%)

60 (37.3%)



04 (23.5%)

43 (26.7%)




21 (61.8%)

176 (54.7%)



13 (38.2%)

146 (45.3)




n = 18

n = 147




13 (72.2%)

54 (36.7%)



04 (22.2%)

53 (36.1%)



01 (5.6%)

40 (27.2%)




30 (73.4%)

161 (54.8%)



06 (16.6%)

133 (45.2%)




n = 18

n = 149




02 (11.1%)

25 (16.4%)



09 (50%)

66 (44.3%)



07 (38.9%)

58 (38.9%)




13 (36.2%)

116 (38.9%)



23 (63.8%)

182 (61.1%)




n = 18

n = 124




10 (61.9%)

75 (59.5%)



03 (14.3%)

27 (22.3%)



05 (23.8%)

22 (18.2%)




23 (63.9%)

177 (71.4%)



13 (36.1%)

71 (28.6%)




16 (88.9%)

114 (91.9%)



02 (11.1%)

10 (8.1%)




34 (94.5%)

238 (96%)



02 (5.5%)

10 (4%)




n = 18

n = 119




16 (88.9%)

36 (30.3%)



00 (0.0%)

61 (51.3%)



02 (11.1%)

22 (18.5%)




32 (88.9%)

133 (55.9%)



04 (11.1%)

105 (44.1%)



n = 18

n = 133




16 (88.9%)

66 (49.6%)



00 (0.0%)

25 (18.8%)



02 (11.1%)

42 (31.6%)




32 (88.9%)

157 (59%)



04 (11.1%)

109 (41%)


* p < 0.05.

Finally, multifactorial analysis was performed to predict which polymorphisms most influenced spontaneous viral clearance (Table 3). The results show that the IL-10 (−1082) (OR 12.848 p = 0.002) and IL-28B (rs12979860) (OR 11.007 p = 0.006) gene polymorphisms have a greater influence.
Table 3

Multifactorial analysis of association of IL-10, IL-4 and IL-28B gene polymorphisms with spontaneous viral clearance

Gene polymorphism

OR (odds ratio)

95% CI (confidence interval)

P (value)

IL-10 (−1082)





IL-28B (rs12979860)





IL-28B (rs8099917)





IL-4 (+33)






This study aims to evaluate the genotype and allele frequencies of IL-10 C-592A, C-819 T and A-1082 G, IL-4 C + 33 T, IFN-γ T + 874A, and TNF-α G-238A, G-308A, a group of cytokines representative of TH1 and TH2 response, respectively, and IL28B Crs12979860T, Trs8099917G a cytokine associated with the induction of antiviral state in the cell and its association with the outcome of HCV infection in a group of Brazilian patients.

The allele C of the IL-4 gene is more present in the acute hepatitis C group than chronic group. To our knowledge, this is the first reported association study of IL-4 T + 33C polymorphism and spontaneous viral clearance in hepatitis C. During the course of hepatitis C, the IL-4 (+33) T allele is associated with higher expression of IL-4 gene[17] and with recurrence of infection after liver transplantation due to hepatitis C and more severe hepatic lesion[18]. The high production of IL-4 by the IL-4 (+33) TT genotype leads to a decrease in viral elimination by down regulation of the TH1 response, thereby affecting control of the viral infection. Thus, an increase in IL-4 levels may lead to an increase in liver injury[19]. On the other hand, no association was found between the IL-4 (−589) gene polymorphism and chronic hepatitis C[20].

The mechanisms responsible for the observed associations between IL-10 polymorphisms and viral infection are still unclear, but appear to be related to the level of IL-10 gene expression and the corresponding effects on the TH1 response and modulation of inflammation. SNPs in the promoter region of the IL-10 gene have been associated with low levels of IL-10 and with chronic inflammatory response in many diseases[8, 9]. Individuals with IL-10 (−1082) GG genotype produce higher levels of IL-10 than GA or AA individuals[21]. Also, IL-10 is a potent inhibitor of pro-inflammatory mediators such as IL-1, TNF-α, IL-6[10] and IFN-γ[11]. Theoretically, high production of IL-10 could facilitate viral escape by down regulating the protective TH1 response, but at the same time be beneficial to the patient due to its anti-fibrogenic properties that could lead to a slow progression of liver disease[12]. In this study, the AA genotype for IL-10 (−1082) was more frequently observed in patients with chronic hepatitis C when compared to those that resolved infection spontaneously. The higher prevalence of genotype AA, associated with low IL-10 production, may lead to a lower efficiency in the antiviral immune response. Our results suggest that a higher production of IL-10 may be associated with spontaneous viral clearance. In agreement with our results, Lio et al., 2003,[13] described an association between high IL-10 production and viral clearance. Thus, the predominance of IL-10 (−1082) GG genotype, associated with high IL-10 gene expression, in patients with spontaneous viral clearance may contribute to the natural history of HCV clearance. The two other IL-10 gene polymorphisms described (−819 and −592) are in linkage disequilibrium and no association with HCV infection was observed[13, 21].

Gajewski et al., 1989, demonstrated that low levels of IFN-γ were associated with persistent HCV infection[14]. IFN-γ gene polymorphisms influence its expression, changing the levels of the cytokine, which may lead to different outcomes of the viral infection as mentioned above. In this study, no differences were found in the distribution of genotypic and allelic frequencies between patients with acute hepatitis C that cleared spontaneously and patients with chronic hepatitis C infection. These results are in agreement with those described by Pereira et al., 2008[22]. However Ben-Ari et al., 2004[23] reported the association of low expression genotypes of IFN-γ T + 874A polymorphism with early recurrent hepatitis C after liver transplantation. The association of the IFN-γ T + 874A polymorphism and chronicity of HCV infection is, however, still controversial.

The persistence of the virus and the response to antiviral therapy have been suggested to be associated with the production of inappropriate levels of TNF-α[24]. Nevertheless, this study did not find any differences in the distribution of genotypic and allelic frequencies, of the polymorphisms −238 and −308 of TNF-α, between patients with spontaneous viral clearance and patients with chronic hepatitis C, which is in accordance with other studies[13, 22].

Several studies have demonstrated an association of SNPs in the IL-28B gene with response to treatment and spontaneous viral elimination in patients with HCV. Two of these polymorphisms, known as rs8099917 and rs12979860, have been strongly associated with non-response to treatment[15, 16, 2529]. Our study shows that the genotypic frequency for the two polymorphisms in the IL-28B gene was associated with spontaneous viral clearance. Both polymorphisms, rs12979860 and rs8099917, were associated with spontaneously viral clearance in comparison with the chronically infected patients. The CC and TT genotypes (for rs12979860 and rs8099917, respectively) correspond to a positive predictive value of 89% for spontaneous viral clearance. These genotypes were also associated with spontaneous clearance of HCV in other studies[15, 25, 26, 30]. These associations presumably are related to the ability of IL-28B to induce the antiviral state. In addition, when analyzing the influence of these polymorphisms in spontaneous viral clearance, we found a strong association with IL-10 (−1082) and IL-28B (rs12979860) gene polymorphisms, while IL-4 (+33) and IL-28B (rs8099917) gene polymorphisms had a lower influence on spontaneous viral clearance. Since the age of infection of chronic hepatitis C patients could not be determined, a limitation of the study, the ages of infection in both groups could have been different. We therefore cannot exclude the influence of different ages of infection on the observed associations. In summary, our study shows that IL-10 and IL-28B gene polymorphims have a greater, and IL-4 gene polymorphism a lower, influence on the clinical outcome of HCV infection in a Brazilian population.


In conclusion: our findings show that polymorphisms in cytokine genes related to the immune response may influence the outcome of acute HCV of infection by the hepatitis C virus.

Patients and methods

A cross-sectional study of 161 individuals with chronic HCV infection attending the Liver Clinic of the Clementino Fraga Filho University Hospital (HUCFF) were selected from 2008 to 2010 and a cohort of 18 patients with acute hepatitis C and spontaneous viral clearance were selected from the Viral Hepatitis Clinic of the Oswaldo Cruz Foundation (FIOCRUZ). This cohort of patients with acute HCV infection was previously evaluated by clinical and laboratory parameters[31]. Patients with undetected HCV RNA in three consecutive tests within 12-months of follow-up were considered as having spontaneous viral clearance. Further details were described elsewhere[31]. The inclusion criteria for chronic hepatitis C patients were: detectable anti-HCV antibodies with detectable serum, HCV RNA for 6 months of follow up, and a liver biopsy with characteristics of chronic HCV infection. Patients with clinical diagnosis of compensated liver cirrhosis (Child-Pugh A) were also included. Exclusion criteria were: HBV or HIV co-infection, alcohol ingestion, other etiologies of chronic liver disease and patients with HCV infection who were submitted to organ transplant. The age at HCV infection of chronic patients could not be determined. Written informed consent was obtained from each patient. The Research and Ethics Committee board of the HUCFF approved the study protocol.

Genomic DNA was extracted from peripheral blood using standard inorganic salting-out procedures[32]. IFN-γ +874 T/A, IL-4 +33C/T, TNF-α -238 G/A, -308 G/A, IL-10 -592C/A, -819C/T and -1082A/G and IL28B rs12979860 C/T and rs8099917T/G gene polymorphisms were genotyped using PCR and specific primers as follows: IFN-γ, F-5-GGAACTTCGTTGCTCACTGGG-3 and R-5-CTATTACATCTACTGTGCCTTCCTG-3 in a 35 cycles at 94oC for 30 seconds, 58oC for 45 seconds and 72oC for 1 min; IL-4, F- 5- CAATGTAAACTCATTTTCCCTCG-3 and R-5-AGAAATACTGAGAGCATCACCAG-3 in 35 cycles at 94°C for 30 s, 54°C for 45 s and 72oC for 1 min; IL-10, C-592A, C-819 T and A-1082 G F- 5-CTCGTCGCAACCCAACTGGC-3 and R-5-CCTAGGTCACAGTGACGTGG-3 in 35 cycles at 94o C for 30 s, 55oC for 45 s and 72o C for 1 min; TNF-α G-238A, G-308A F- 5-TCCTGCATCCTGTCTGGAAGT-3 and R-5-AgggAgCgTCTgCTggCTgggTg-3 in 35 cycles at 94o C for 30 s, 60°C for 45 s and 72°C for 1 min. Il-28B rs12979860 F- 5- TCGCCAGGGCCCCTAACCTCTGC-3 and R-5- CGCCCAGCAGGCGCCTCTCCTA-3 in 35 cycles at 94o C for 30 s, 58oC for 45 s and 72o C for 1 min and IL-28B rs8099917 F-5-CCACTTCTGGAACAAATCGTC-3 and R-5-GATACGCTATAATTAAAGATGTGGA-3 in 35 cycles at 94o C for 30 s, 54oC for 45 s and 72o C for 1 min. The amplified products were sequenced using the DYEnamic™ ET Dye Terminator Cycle Sequencing kit for MegaBACE (Amersham Pharmacia Biotech Inc.).

Statistical analysis was carried out using SPSS v15 Statistical System (Chicago, IL,USA). The Chi-square or Fisher’s exact method was used to determine deviations from Hardy-Weinberg Equilibrium and to compare genotypes, allele and phenotype frequencies. The binary logistic regression analysis was performed with the polymorphisms that showed significant differences in association analyses (P values < 0.05).

Financial support

CNPq, CAPES, FAPERJ, CGLAB/Ministry of Health and NIH,



Hepatitis C virus


Single nucleotide polymorphism.



We thank Jorge Luiz Coutinho, César Félix Schmidt, Cláudio Nunes Pereira and Paulo Sergio Fonseca de Sousa for technical assistance. This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação Carlos Chagas Filho de Apoio à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil. The acute HCV cohort from the Oswaldo Cruz Institute/Oswaldo Cruz Foundation was supported by the National Institute of Health (NIH) grant AI066345-05, and CGLAB/Ministry of Health, Brazil.

Authors’ Affiliations

Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro
Instituto Federal de Educação Ciência e Tecnologia do Rio de Janeiro
Serviço de Hepatologia, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro
Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal do Rio de Janeiro
Instituto Oswaldo Cruz, Fundação Oswaldo Cruz
Instituto Nacional para Pesquisa Translacional em Saúde e Ambiente na Região Amazônica, Conselho Nacional de Desenvolvimento Científico e Tecnológico/MCT


  1. Seeff LB: Natural history of chronic hepatitis C. Hepatology. 2002, 36 (suppl 1): S35-S46.PubMedView ArticleGoogle Scholar
  2. Barrett S, Ryan E, Crowe J: Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol. 1999, 30: 979-983. 10.1016/S0168-8278(99)80249-9.PubMedView ArticleGoogle Scholar
  3. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenfelde KH, Rittner C: Tumor necrosis factor alpha promoter polymorphism at position −238 is associated with chronic active hepatitis C infection. J Med Virol. 1998, 54: 173-177. 10.1002/(SICI)1096-9071(199803)54:3<173::AID-JMV5>3.0.CO;2-2.PubMedView ArticleGoogle Scholar
  4. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR: Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000, 31: 828-833. 10.1053/he.2000.6253.PubMedView ArticleGoogle Scholar
  5. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T: Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology. 2002, 35: 937-946. 10.1053/jhep.2002.32470.PubMedView ArticleGoogle Scholar
  6. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM: Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology. 1996, 24: 6-9. 10.1002/hep.510240102.PubMedView ArticleGoogle Scholar
  7. Quiroga JA, Martin J, Pardo M, Carreno V: Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig Dis Sci. 1994, 39: 2485-2496. 10.1007/BF02087671.PubMedView ArticleGoogle Scholar
  8. Luomala M, Lehtimaki T, Huhtala H, Ukkonen M, Koivula T, Hurme M, Elovaara I: Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurol Scand. 2003, 108: 396-400. 10.1034/j.1600-0404.2003.00165.x.PubMedView ArticleGoogle Scholar
  9. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O’Brien TR, Vlahov D, Buchbinder S, Giorgi J, et al: Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA. 2000, 97: 14467-14472. 10.1073/pnas.97.26.14467.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB: Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004, 22: 929-979. 10.1146/annurev.immunol.22.012703.104622.PubMedView ArticleGoogle Scholar
  11. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV: In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet. 1999, 26: 1-3. 10.1046/j.1365-2370.1999.00122.x.PubMedView ArticleGoogle Scholar
  12. Nelson DR, Lauwers GY, Lau JY, Davis GL: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000, 118: 655-660. 10.1016/S0016-5085(00)70134-X.PubMedView ArticleGoogle Scholar
  13. Lio D, Caruso C, Di Stefano R, Colonna Romano G, Ferraro D, Scola L, Crivello A, Licata A, Valenza LM, Candore G, et al: IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol. 2003, 64: 674-680. 10.1016/S0198-8859(03)00080-6.PubMedView ArticleGoogle Scholar
  14. Gajewski TF, Joyce J, Fitch FW: Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol. 1989, 143: 15-22.PubMedGoogle Scholar
  15. di Iulio J, Ciuffi A, Fitzmaurice K, Kelleher D, Rotger M, Fellay J, Martinez R, Pulit S, Furrer H, Günthard HF, et al: Estimating the net contribution of interleukin-28B variant to spontaneous hepatitis C virus clearance. Hepatology. 2011, 531: 1446-1454.View ArticleGoogle Scholar
  16. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al: Genome-wide association of IL-28B with response to pegylated interferon-α and ribavirina therapy for chronic hepatitis C. Nat Genet. 2009, 1-5.Google Scholar
  17. Hershey GK: IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003, 111: 677-690. 10.1067/mai.2003.1333.PubMedView ArticleGoogle Scholar
  18. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 1996, 24: 759-765. 10.1002/hep.510240402.PubMedView ArticleGoogle Scholar
  19. Dharancy S, Podevin P, Aoudjehane L, Batteux F, Rosenberg AR, Soubrane O, Calmus Y, Conti F: Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Transplantation. 2007, 83: 906-911. 10.1097/ ArticleGoogle Scholar
  20. Chen TY, Hsieh YS, Wu TT, Yang SF, Wu CJ, Tsay GJ, Chiou HL: Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl Res. 2007, 150: 116-121. 10.1016/j.trsl.2007.01.007.PubMedView ArticleGoogle Scholar
  21. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997, 24: 1-8. 10.1111/j.1365-2370.1997.tb00001.x.PubMedView ArticleGoogle Scholar
  22. Pereira FA, da Silva NN P, Rodart IF, Carmo TM, Lemaire DC, Reis MG: Association of TGF-beta1 codon 25 (G915C) polymorphism with hepatitis C virus infection. J Med Virol. 2008, 80: 58-64. 10.1002/jmv.21011.PubMedView ArticleGoogle Scholar
  23. Ben-Ari Z, Pappo O, Druzd T, Sulkes J, Klein T, Samra Z, Gadba R, Tambur AR, Tur-Kaspa R, Mor E: Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine. 2004, 27: 7-14. 10.1016/j.cyto.2004.03.009.PubMedView ArticleGoogle Scholar
  24. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY: Tivation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997, 42: 2487-10.1023/A:1018804426724.PubMedView ArticleGoogle Scholar
  25. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al: IL-28B is association with response to chronic hepatitis C interferon-alpha and ribavirina therapy. Nat Genet. 2009, 10: 1100-1104.View ArticleGoogle Scholar
  26. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al: Genetic variation in IL-28B predicts hepatitis C treatment induced viral clearance. Nature. 2009, 461: 399-401. 10.1038/nature08309.PubMedView ArticleGoogle Scholar
  27. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M: lambda-Interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res. 2010, 40: 449-460. 10.1111/j.1872-034X.2010.00671.x.PubMedView ArticleGoogle Scholar
  28. Mangia A: IL28B: a new wager in the skyline of hepatitis C virus infection. Dig Liver Dis. 2010, 43: 177-179.View ArticleGoogle Scholar
  29. Doehring A, Hofmann WP, Schlecker C, Zeuzem S, Susser S, Geisslinger G, Sarrazin C, Lotsch J: Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir Ther. 2010, 15: 1099-1106. 10.3851/IMP1689.PubMedView ArticleGoogle Scholar
  30. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterolgy. 2010, 138: 1338-1345. 10.1053/j.gastro.2009.12.056.View ArticleGoogle Scholar
  31. Lewis-Ximenez LL, Lauer GM, Schulze Zur Wiesch J, De Sousa PS, Ginuino CF, Paranhos-Baccalá G, Ulmer H, Pfeiffer KP, Goebel G, Pereira JL, Oliveira de Mendes J, et al: Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis. 2010, 50: 1222-1230. 10.1086/651599.PubMedView ArticleGoogle Scholar
  32. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1998, 16: 1215-View ArticleGoogle Scholar


© Ramos et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.